- Home
- TALO vs IMCR Comparison
TALO vs IMCR Comparison
Compare TALO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TALO | IMCR |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | TALO | IMCR |
|---|---|---|
| Price | $11.06 | $36.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $14.30 | ★ $67.00 |
| AVG Volume (30 Days) | ★ 2.1M | 276.8K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,872,554,000.00 | $379,590,000.00 |
| Revenue This Year | N/A | $32.31 |
| Revenue Next Year | N/A | $10.50 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 0.06 | ★ 28.11 |
| 52 Week Low | $6.23 | $23.15 |
| 52 Week High | $12.20 | $40.72 |
Technical Indicators
Market Signals| Indicator | TALO | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 49.23 | 50.52 |
| Support Level | $10.64 | $35.41 |
| Resistance Level | $11.39 | $37.17 |
| Average True Range (ATR) | 0.37 | 1.71 |
| MACD | -0.11 | -0.21 |
| Stochastic Oscillator | 24.44 | 24.54 |
Price Performance
Historical ComparisonAbout TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.